Epoetin beta pegol, but not recombinant erythropoietin, retains its hematopoietic effect in vivo in the presence of the sialic acid-metabolizing enzyme sialidase.

MLA

Aizawa, Ken, et al. “Epoetin Beta Pegol, but Not Recombinant Erythropoietin, Retains Its Hematopoietic Effect in Vivo in the Presence of the Sialic Acid-Metabolizing Enzyme Sialidase.” International Journal of Hematology, vol. 104, no. 2, Aug. 2016, pp. 182–89. EBSCOhost, https://doi.org/10.1007/s12185-016-2000-8.

APA

Aizawa, K., Kawasaki, R., Tashiro, Y., Hirata, M., Endo, K., & Shimonaka, Y. (2016). Epoetin beta pegol, but not recombinant erythropoietin, retains its hematopoietic effect in vivo in the presence of the sialic acid-metabolizing enzyme sialidase. International Journal of Hematology, 104(2), 182–189. https://doi.org/10.1007/s12185-016-2000-8

Chicago

Aizawa, Ken, Ryohei Kawasaki, Yoshihito Tashiro, Michinori Hirata, Koichi Endo, and Yasushi Shimonaka. 2016. “Epoetin Beta Pegol, but Not Recombinant Erythropoietin, Retains Its Hematopoietic Effect in Vivo in the Presence of the Sialic Acid-Metabolizing Enzyme Sialidase.” International Journal of Hematology 104 (2): 182–89. doi:10.1007/s12185-016-2000-8.